Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Pinetree announced the exclusive option and global license agreement with AstraZeneca for its preclinical EGFR degrader candidate, with $45 million in upfront…
Pinetree Therapeutics announced AstraZeneca's exercise of the exclusive option to license the global rights to PTX-299, a first-in-class bispecific antibody…
AstraZeneca converted a preclinical option into an exclusive global license agreement with Pinetree Therapeutics, triggering a $25 million payment. Pinetree…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
AstraZeneca exercised its exclusive option to globally license Pinetree's preclinical EGFR degrader PTX-299, triggering a $25M option-closing payment plus future development, regulatory and commercial milestones and tiered royalties; total potential value exceeds $500M.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Pinetree Therapeutics, Inc. (this deal) | 2026 | $500M | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2026 deals · AstraZeneca PLC deals · Oncology deals